Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for ...
The US regulator has accepted Cytokinetics' marketing application for the cardiac myosin inhibitor, setting a target action date of 26th September 2025 to complete its review and, according to the ...
Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. Also Read: Edgewise ...
The common presenting symptoms among individuals with HCM include dyspnea, angina, and presyncope or syncope. Chest pain may occur at rest or be precipitated by exertion or, among those with LVOTO ...
Hypertrophic cardiomyopathy (HCM) is an uncommon disease with significant consequences. Since the 1950s, major strides in understanding its etiology and pathogenesis have led to improved ...
After hours: February 14 at 7:59:24 PM EST Loading Chart for CYTK ...
After hours: 7:59:24 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback